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To evaluate the effect of population-based cervical cancer screening on the occurrence of cervical cancer in The Netherlands, we
investigated the incidence and survival of cervical cancer registered by a cancer registry in the Greater Amsterdam area. The
incidence rate of squamous cell carcinoma decreased significantly from 9.2/100000 women in 1988 to 5.9/100000 in 2000
(Po0.001). The incidence rate of adenocarcinomas remained stable. After adjustment for age, stage and lymph node involvement,
the relative risk of death was 1.6 times higher for patients with adenocarcinomas than for patients with squamous cell carcinoma
(95% CI 1.2–2.1). The decreased survival was related to histological type, as the effect remained significant after correction for
confounding factors. Over time, the prognosis of women with squamous cell carcinoma improved significantly. No significant change
was observed for women diagnosed with adenocarcinoma. These results suggest that the screening programme in The Netherlands
as executed in the Greater Amsterdam area is associated with a decreased incidence and increased survival of patients with
squamous cell carcinoma, but fails to detect (pre)malignant lesions of adenocarcinoma. Since more than 92% of adenocarcinomas
and its precursors contain high-risk HPV, adding HPV testing to cytologic screening might improve the present screening programme
in detecting adenocarcinoma and its precursor lesions.
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Population-based cervical cancer screening has led to a decrease in
the incidence of cervical cancer (Gustafsson et al, 1997; Vizcaino
et al, 2000). However, recent data suggest that the decrease in
incidence is caused by a decrease of squamous cell carcinoma,
while the incidence of adenocarcinoma of the cervix shows no
change or sometimes even an increase (Anttila et al, 1999;
Bergstrom et al, 1999; Hemminki et al, 2001; Liu et al, 2001).
It has been suggested that the unchanged or even increased
incidence of adenocarcinoma of the cervix is the result of
systematic underscreening of cervical smears for (pre)malignant
changes of adenocarcinoma of the cervix (Parkin et al, 1985;
Mitchell et al, 1995; Stockton et al, 1997). Moreover, patients with
adenocarcinomas of the cervix are considered to have a decreased
survival compared to patients with squamous cell carcinomas
(Hopkins and Morley, 1991; Lai et al, 1999; Nakanishi et al, 2000;
Grisaru et al, 2001). It has been suggested that this decreased
survival is associated with higher stages of disease with which
patients with adenocarcinomas are detected.
Here, we report on the incidence and survival rates of cervical
cancer cases registered by a cancer registry in a large geographi-
cally defined region of The Netherlands, the Greater Amsterdam
area. Special attention was paid to trends in incidence and survival
rates for cases of squamous cell carcinoma and adenocarcinoma.
MATERIALS AND METHODS
Data collection
The cancer registry of the Comprehensive Cancer Centre
Amsterdam (CCCA, ‘Amsterdam Cancer Registry’) is a popula-
tion-based cancer registry since 1988, and part of the nationwide
Netherlands Cancer Registry as of 1989. It covers two out of 12
Dutch provinces: Noord-Holland and the major part of Flevoland.
The population of the CCCA region increased from 2.50 million on
1 January, 1988 to 2.80 million on 1 January, 2001. All malignant
tumours were registered in all 20 hospitals in the region,
comprising two university hospitals and a specialised cancer
hospital (where cancer patients are treated).
Clinical information and pathology data were extracted from the
medical records. Apart from demographic data, data were collected
on tumour site, morphological classification (according to the
International Classification of Diseases for Oncology) and stage of
the tumour. The fourth edition of the TNM-classification was used
whenever applicable (Hermanek and Sobon, 1987). In 1988–1993,
the FIGO stage was registered separately, and after 1993 the FIGO
stage was derived from TNM stage. Data concerning participation
in cervical cancer screening programmes were not available.
For this study, all cervical cancer cases diagnosed between 1
January, 1988 and 31 December, 2000 were selected from the
cancer registry. The following tumours were excluded: noninvasive
tumours and tumours diagnosed in patients living outside the
CCCA region. Patients diagnosed in a hospital outside the region, Received 28 February 2003; revised 2 May 2003; accepted 16 May 2003
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vital status of all patients was collected in the hospitals and from
general practitioners. However, the majority of the information on
vital status was obtained from record linkage of computerised data
on all deceased persons in the study period that were made
available by 51 of the 74 municipalities in the CCCA region
(covering more than 85% of the population). Inquiries about the
vital status of patients living in the other 23 municipalities were
made at the municipal population registers and at the Central
Office for Genealogy of The Netherlands, The Hague. Less than 1%
of the cases were lost to follow-up. In the survival analyses, cases
diagnosed in 1998–2000 were excluded, because of the short
period of follow-up. Tumours first diagnosed at autopsy, second
(or third, etc.) tumours and noncarcinomas were also excluded
from the survival analyses. Follow-up of the patients diagnosed in
1988–1997 was complete until at least 1 January, 1999.
Population data of The Netherlands were obtained from
Statistics Netherlands (CBS, Voorburg/Heerlen, The Netherlands).
Data from Statistics of Netherlands were also obtained with respect
to the survival of the general Dutch population.
Statistical analysis
Incidence of cervical cancer was calculated per 100000 person
years. Direct standardisation was used for age adjustment with
respect to the European standard population, and the European
standardised rates (ESRs) were calculated. Trends in the incidence
of the ESR were investigated by calculating the estimated annual
percent change (EAPC) (Visser et al, 2001). For the analyses, cases
were divided into squamous cell carcinoma, adenocarcinoma
including adenosquamous carcinoma and other histological type
(i.e., other and unspecified carcinomas, sarcomas and undefined
tumours). Age was divided into 15-year categories. However, age
categories of 15–29 and 30–44 years were analysed jointly in the
survival analyses, based on the low number of cases (n¼90) in the
category of 15–29 years. Differences in distribution over stage and
age categories were assessed with w
2 statistics.
Relative survival and 95% confidence intervals (CIs) were
calculated as a measure of disease-specific survival (Hakulinen and
Abeywickrama, 1985). The relative survival is the ratio between
crude and expected survival and is close to disease-specific
survival. We did not calculate disease-specific survival, because the
cause of death was not available as linkage with the death registry
in The Netherlands is not possible.
The Cox multivariate regression analysis for survival was
performed to investigate survival. Associations were examined
for all cases, and for cases of squamous cell carcinoma and
adenocarcinoma separately. In the analyses, the FIGO classification
was used to adjust for stage. Lymph node status is not considered
in the FIGO classification for cervical carcinoma, and therefore it
was introduced in the analyses as a separate variable. For cases
diagnosed in 1988, TNM was not registered, so these cases were
classified as ‘nodal involvement unknown’. Age, stage and nodal
involvement were divided into categories and entered into the
model as dummy variables. P-values of 0.05 or less were
considered statistically significant. Using STATA 6.0 for Windows,
hazard ratios (HRs) and 95% CIs were calculated.
RESULTS
From 1988 up to 2000, 1925 patients were diagnosed with invasive
cervical cancer (Table 1). The annual number of incident cases of
cervical cancer decreased from 157 patients registered in 1988 to
135 patients in 2000. The ESR decreased from 11.8/100000 women
in 1988 to 8.2/100000 women in 2000. The total ESR decreased by
2.7% annually (P¼0.001). This decrease in incidence was mainly
caused by a decrease in the incidence of squamous cell carcinoma
cases, as the EAPC in ESR for squamous cell carcinomas was
 3.2% (Po0.001). For adenocarcinomas, there was no statistically
significant trend in the incidence (EAPC  1.1%, P¼0.54). The
incidence of other cervical malignancies decreased with 1.4%
annually (P¼0.74). During the study period, the contribution of
adenocarcinomas to the total number of malignancies increased
from 16% in 1988–1990 to 18% in 1998–2000.
The median age of patients with adenocarcinoma was 3 years
below the median age of patients with squamous cell carcinoma,
that is 44 years (range: 18–92) and 47 years (range: 19–98),
respectively (Po0.05). Age-specific incidence was highest in age
groups 35–39 and 70–84 years for squamous cell carcinoma
patients, and the age-specific incidence was highest in the age
group 35–49 years for adenocarcinoma patients (Figure 1).
Younger patients were more often diagnosed in early stages of
cancer than older patients (Figure 2). Of women 15–29 years, 82%
were diagnosed with FIGO stage I disease, while only 15% of
patients 75 years and over were diagnosed with FIGO stage I
disease. Only 2% of the patients in the age category 15–29 years
were diagnosed in stage IV, while 14% of the oldest patients were
Table 1 Incidence of cervical cancer in the Greater Amsterdam area, the Netherlands, 1988–2000
SCC AdCx Other Total
Year Cases ESR Cases ESR Cases ESR Cases ESR
1988 128 9.7 22 1.6 7 0.5 157 11.8
1989 129 9.5 24 1.8 2 0.2 155 11.5
1990 125 8.8 29 2.2 4 0.3 158 11.3
1991 111 7.6 19 1.2 4 0.3 134 9.0
1992 134 9.5 28 1.9 6 0.4 168 11.9
1993 126 8.9 30 2.1 2 0.2 158 11.1
1994 114 7.5 26 1.8 4 0.3 144 9.6
1995 120 7.8 25 1.7 3 0.2 148 9.7
1996 107 6.8 18 1.2 7 0.4 132 8.5
1997 117 7.4 32 2.1 4 0.2 153 9.6
1998 118 7.5 33 2.1 2 0.1 153 9.6
1999 108 6.8 17 1.1 5 0.3 130 8.2
2000 100 6.1 26 1.6 9 0.6 135 8.2
EAPC  3.2%  1.1%  1.4%  2.7%
P-value o0.001 0.54 0.74 0.001
SCC¼squamous cell carcinoma; AdCx¼adeno(squamous)carcinoma; ESR¼European standardised rate; EAPC¼
estimated annual percent change.
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carcinomas and 65% of patients with adenocarcinomas were
diagnosed in FIGO stage I (P¼0.003). However, adenocarcinomas
were diagnosed less often in the microinvasive (i.e., Ia) stage of the
disease than squamous cell carcinomas (15 and 22%, respectively)
(Po0.0001). The percentage of cases diagnosed in FIGO stage IV
did not differ statistically significantly between squamous cell
carcinomas (7%) and adenocarcinomas (6%) (P¼0.71). During
the study period, there were no statistically significant changes in
distribution over the stages.
During 1988–1997, there were 1441 patients with cervical
carcinoma in the region of the CCCA, 480 of whom died
(33.3%). The median follow-up time was 56 months (range: 0–
165 months). The overall 5-year relative survival of cervical
carcinoma was 71% (Table 2). Relative survival decreased from
85% for women o45 years to 41% for women of 75 years and over.
Patients with FIGO stage I had a relative survival of 91%
decreasing to 16% for tumours diagnosed in FIGO stage IV.
Relative survival of squamous cell carcinomas was 72% (95% CI:
69–75%), and somewhat lower for adeno(squamous)carcinomas
(66%, 95% CI: 59–72%).
Table 3 displays the results of the multivariate analysis of
survival for all types of cervical cancer. Compared to FIGO stage I,
all other stages had significantly increased HRs. Lymph node
status is not considered in the FIGO classification for cervical
carcinoma. For cases diagnosed in 1988, TNM was not registered
and these cases were classified as ‘nodal involvement unknown’.
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Figure 1 Age-specific incidence rates by histologic type of patients in the
Greater Amsterdam area 1988–2000.
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Figure 2 Stage at diagnosis by 15-year age category of patients in the
Greater Amsterdam area, the Netherlands, 1988–2000.
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Figure 3 Stage at diagnosis by histologic type of patients in the Greater
Amsterdam area, the Netherlands, 1988–2000.
Table 2 Relative survival of patients with cervical carcinoma in the Greater Amsterdam area, the
Netherlands in 1988–1997
Variable Category Cases 5-year survival (%) 95% CI (%)
All cases 1441 71 68–74
Age o45 665 85 82–88
45–59 321 72 66–77
60–74 285 54 47–60
75+ 170 41 31–52
FIGO stage I 831 91 88–93
II 304 57 50–64
III 168 35 27–43
IV 99 16 9–24
Unknown 39 44 27–61
Histology SCC 1169 72 69–75
AdCx 244 66 59–72
Other/unspecified carcinoma 28 60 38–78
CI¼confidence interval; SCC¼squamous cell carcinoma; AdCx¼adeno(squamous)carcinoma.
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increased risk of death (HR 2.1, 95% CI 1.6–2.7). Tumour
histology was investigated with squamous cell carcinoma cases as
reference category. Univariately, the HR of adenocarcinomas was
slightly increased (HR 1.1), while other/unspecified carcinomas
were associated with a significant increase in risk. The increased
risk for other/unspecified carcinomas disappeared with multi-
variate adjustment, indicating that the increase in risk was caused
by confounding by age and stage. After adjustment, the HR for
adenocarcinomas was significantly increased (HR 1.6, 95% CI 1.3–
2.1). Over time, the prognosis of patients with cervical cancer
improved, as the multivariate HRs were decreased for the periods
1991–1993 and 1994–1997 as compared to the reference period
1988–1990. Adjustment for stages 1a and 1b separately did not
alter these findings substantially (data not shown).
Squamous cell carcinoma cases and adenocarcinoma cases were
also analysed separately (Table 4). Both for squamous cell
carcinomas and adenocarcinomas, survival decreased with in-
creasing age, higher FIGO stage and positive lymph nodes at
diagnosis (data not shown). The improvement in survival of
women with cervical cancer during the period 1988–1997 was
associated with cases of squamous cell carcinoma only. Survival of
women with cervical adenocarcinoma did not improve during the
study period (Table 4).
DISCUSSION
Our results show that the incidence of cervical cancer has
decreased significantly during the period 1988–2000, and that
this decrease is caused by a decrease in the incidence of squamous
cell carcinomas. In multivariate analyses, survival for patients
diagnosed with adenocarcinoma of the cervix was significantly
lower than survival for patients with squamous cell carcinoma.
This indicates that women with adenocarcinoma of the uterine
cervix have an intrinsically increased risk of death compared with
women with squamous cell carcinoma independent of stage, age
and nodal involvement.
Table 3 Relative risk of death for patients in the Greater Amsterdam area, The Netherlands, with cervix
carcinoma diagnosed in 1988–1997 (n¼1441)
Univariate Multivariate
a
Factor Cases Hazard ratio 95% CI Hazard ratio 95% CI
FIGO stage
I 831 1 Reference 1 Reference
II 304 4.9* 3.8–6.3 3.3* 2.6–4.7
III 168 10* 7.9–13 6.4* 4.7–8.5
IV 99 19* 14–25 11* 7.6–15
Unknown 39 9.2* 5.9–14 5.7* 3.6–9.1
Nodal involvement
No 563 1 Reference 1 Reference
Yes 668 3.2* 2.5–4.1 2.1* 1.6–2.7
Unknown
b 210 1.6* 1.3–2.0 1.4* 1.1–1.8
Morphological type
SCC 1169 1 Reference 1 Reference
AdCx 244 1.1 0.9–1.4 1.6* 1.3–2.1
Other/unspec. carcinoma 28 1.7 1.0–3.0 0.7 0.4–1.2
Year of diagnosis
1988/1990 451 1 Reference 1 Reference
1991/1993 442 0.7* 0.6–0.9 0.8* 0.6–1.0
1994/1997 548 0.8 0.7–1.1 0.8 0.6–1.0
aAdjusted for age category and all other factors in the table.
bCases diagnosed in 1988 were all classified as unknown.
*Po0.05.CI¼confidence interval; SCC¼squamous cell carcinoma; AdCx¼adeno(squamous)carcinoma.
Table 4 Relative risk of death for patients in the Greater Amsterdam area, The Netherlands, with cervix
carcinoma diagnosed in 1988–1997 (n¼1441). Year of diagnosis as an indicator of survival, separately for
patients with squamous cell carcinoma and adenocarcinoma
Univariate Multivariate
a
Factor Hazard ratio 95% CI Hazard ratio 95% CI
Year of 1988/1990 1 Reference 1 Reference
diagnosis; 1991/1993 0.9 0.5–1.5 0.8 0.5–1.5
AdCx 1994/1997 1.0 0.6–1.6 1.2 0.7–2.0
Year of 1988/1990 1 Reference 1 Reference
diagnosis; 1991/1993 0.7* 0.6–0.9 0.8* 0.6–1.0
SCC 1994/1997 0.8 0.6–1.0 0.8* 0.6–1.0
aAdjusted for age, stage and nodal involvement. *Po0.05. CI¼confidence interval; AdCx¼adeno(squamous)carcinoma;
SCC¼squamous cell carcinoma.
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within a geographically defined region in The Netherlands: the
Greater Amsterdam area. As data were obtained by the Regional
Cancer Registry, we were able to study an unbiased population of
women with different histological types of cervical cancer for
factors associated with survival. In this study, the histological
verification rate was 99.8%. Nationally, the histological verification
rate for cervical cancer is 99.7%, indicating a high accuracy rate of
the Dutch Cancer Registries (Visser et al, 1997).
In this study, knowledge of participation in cervical cancer
screening preceding the diagnosis of cancer may have been
relevant. We did not have data on either individual Pap smear
taking or participation in the nationwide screening programme in
this group of women with cervical carcinoma. Cytological screen-
ing on an individual basis has been available for women in this
region of The Netherlands since the 1970s. A nationwide screening
programme aimed at specific age categories was initiated in 1988.
Between 1988 and 1996, women aged 34–54 years were screened
triannually, and from 1996 onwards, women aged 30–60 years are
screened every 5 years. Overall, the coverage of cervical cancer
screening activities over a period of 5 years is approximately 80%
(van Ballegooijen and Hermens, 2000). However, regional partici-
pation in each screening round of the population-based pro-
gramme is lower (60–70%). Even without data on screening
participation, some findings do suggest the efficacy of screening in
this region of The Netherlands. The incidence of cervical
squamous cell carcinoma decreased significantly, while no
statistically significant change in the incidence of adenocarcinoma
was found. Previous studies have reported that cervical adeno-
carcinoma and its preinvasive stages are diagnosed less efficiently
by Pap smear screening than squamous cell lesions (Mitchell et al,
1995; Stockton et al, 1997). In some countries, not only the absence
of a decrease in incidence (Sigurdsson, 1993; Nieminen et al, 1995),
but also increases in the incidence of cervical adenocarcinoma
have been described in the presence of a screening programme
(Bergstrom et al, 1999; Hemminki et al, 2001; Liu et al, 2001). One
study even suggested an increase in incidence especially in
younger women (Anttila et al, 1999), whereas older women were
not affected by increases in the incidence rate of cervical cancer.
Our data do not support this trend. Our findings suggest a positive
effect of the screening programme as shown by the decrease in
cervical carcinoma incidence. Increasing screening participation to
obtain an even higher degree of coverage will most likely increase
the efficacy of the screening programme in decreasing the
incidence of cervical cancer.
In our analyses, patients with cervical adenocarcinoma had a
worse prognosis than patients with squamous cell carcinoma after
correction for confounders such as age, stage and nodal
involvement. Previous studies either usually lacked sufficient
numbers of patients with adenocarcinomas (Pilch et al, 2001), or
were not population-based (Hopkins and Morley, 1991; Nakanishi
et al, 2000), or did not make direct comparisons between patients
with squamous cell carcinoma and adenocarcinoma (Benedet et al,
1998). Some studies attributed the decreased survival of women
with adenocarcinoma to differences in histological type (Lai et al,
1999; Grisaru et al, 2001). In our study, patients with adenocarci-
noma presented with more advanced stage I tumours than patients
with squamous cell carcinomas. Still, patients with cervical
adenocarcinoma were slightly younger at diagnosis than patients
with squamous cell carcinoma, 48 and 50 years, respectively. As
the association between adenocarcinomas and a worse prognosis
increased after correction for confounding factors, this indicates
that women with cervical adenocarcinoma have an inherently
worse prognosis than women with squamous cell carcinoma. The
main causal factor for the development of both squamous cell
carcinoma and adenocarcinoma of the uterine cervix is infection
with high-risk types of the human papillomavirus (hrHPV)
(Walboomers et al, 1999; Bosch et al, 2002). There are substantial
differences with respect to the exact type of hrHPV and the
histological diagnosis. Adenocarcinomas are more often associated
with HPV type 18 than squamous cell carcinomas (Bosch et al,
1995, 2002; Andersson et al, 2001; Clifford et al, 2003). Moreover,
HPV 18 has been shown to be associated with a worse prognosis
than other HPV types (Hildesheim et al, 1999; Schwartz et al,
2001), but this finding has been challenged (Pilch et al, 2001). An
intrinsic difference between neoplasically converted squamous and
cylindrical epithelium might also be the cause of the difference in
prognosis, independent of HPV infection.
The survival of patients with squamous cell carcinoma increased
during 1988–1997, while the survival of patients with adenocarci-
nomas did not change significantly. During the study period, there
were no large changes in treatment of patients with cervical cancer
in any stage of the disease. The nationwide screening programme
was introduced in 1988. Theoretically, an improvement in the
prognosis of patients with squamous cell carcinomas might have
been caused by a major change in stage at diagnosis during the
study period. We did not observe such a change in stage at
diagnosis over time (data not shown). However, we cannot exclude
an effect of subtle changes within broad stages, such as a shift from
FIGO 1b to FIGO 1a. Screening, leading to an earlier detection of
cervical cancer even without significant changes in broad FIGO
stage distribution, may contribute to such an effect. We were not
able to find a trend over time in histological lymph node positivity
over all stages of disease, as lymph node sampling is dependent on
stage at diagnosis. In this study, in 31% of women with
adenocarcinoma and 43% of women with squamous cell carcino-
ma, lymph node status was not determined histologically. Stage
migration due to improved staging procedures might also have
contributed to the increased survival. Still, the statistically
significant difference in survival was based on small numbers of
adenocarcinoma cases compared to squamous cell carcinoma
cases. Therefore, caution should be taken into account when
interpreting trends in the survival of adenocarcinoma based on
these data.
The overall 5-year survival rate was 71%. Compared to other
countries in Europe, this is a high survival rate, with only the
Nordic countries having comparable survival rates (Berrino et al,
1999). Other studies have also shown that within Europe, The
Netherlands have a very low incidence, and a very high survival
compared with other countries (Levi et al, 2000). It is reasonable to
attribute these findings to the presence of a nationwide screening
programme, as similar effects on incidence have been described in
other countries with a screening programme (Gustafsson et al,
1997). Whether the effect on survival in the absence of changes in
treatment can be exclusively attributed to the cervical cancer
screening programme, remains a question of debate (Quinn et al,
1999; Sasieni and Adams, 1999).
Our study suggests that the present screening programme for
cervical cancer is efficient in detecting (pre) malignant stages of
squamous cell carcinoma, but fails to detect (pre) malignant stages
of adenocarcinoma (Sasieni and Adams, 2001). Since more than
92% of the adenocarcinomas and its precursors contain hrHPV
(Pirog et al, 2000; Pilch et al, 2001), adding hrHPV testing to
conventional cytological screening might improve the present
screening programme in detecting adenocarcinoma and its
precursor lesions. This should be a focus of further research
concerning the functioning of the screening programme for
cervical cancer.
In conclusion, in the Greater Amsterdam area, the incidence of
squamous cell carcinomas has decreased while there were no
changes in the incidence of adenocarcinoma of the uterine
cervix. Cases of adenocarcinoma of the uterine cervix are
associated with a decreased survival rate compared to patients
with squamous cell carcinoma. This decreased survival is related to
tumour histology itself, since after correction for factors such as
age, stage and lymph node status, the survival of adenocarcinoma
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ypatients is still lower compared with squamous cell carcinoma
patients.
ACKNOWLEDGEMENTS
We gratefully thank all registration clerks of the Amsterdam Cancer
Registry for the collection of data. We thank FJ van Kemenade for
helpful comments on this paper. This study was supported by
Grant 2200.0089 from the Health Research & Development Council
of The Netherlands (ZorgOnderzoek Nederland).
S Bulk, L Rozendaal, O Visser, RHM Verheijen and CJLM Meijer
participated in the conception of the study. S Bulk wrote the
report. O Visser was responsible for the data collection and
statistical analyses. All investigators discussed findings and
critically revised the paper.
REFERENCES
Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E
(2001) The role of human papillomavirus in cervical adenocarcinoma
carcinogenesis. Eur J Cancer 37: 246–250
Anttila A, Pukkala E, Soderman B, Kallio M, Nieminen P, Hakama M (1999)
Effect of organised screening on cervical cancer incidence and mortality
in Finland, 1963–1995: recent increase in cervical cancer incidence. Int J
Cancer 83: 59–65
Benedet J, Odicino F, Maisonneuve P, Severi G, Creasman W, Shepherd J,
Sideri M, Pecorelli S (1998) Carcinoma of the cervix uteri. J Epidemiol
Biostat 3: 5–34
Bergstrom R, Sparen P, Adami HO (1999) Trends in cancer of the cervix
uteri in Sweden following cytological screening. Br J Cancer 81: 159–166
Berrino F, Capocaccia R, Esteve J, Gatta G, Hakulinen T, Micheli A, Sant M,
Verdecchia A (1999) Survival of Cancer Patients in Europe: the
EUROCARE-2 Study. IARC Scientific Publication [No. 151.]. Lyon: IARC
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal
relation between human papillomavirus and cervical cancer. J Clin
Pathol 55: 244–265
Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman
MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human
papillomavirus in cervical cancer: a worldwide perspective. International
biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer
Inst 87: 796–802
Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003) Human
papillomavirus types in invasive cervical cancer worldwide: a meta-
analysis. Br J Cancer 88: 63–73
Grisaru D, Covens A, Chapman B, Shaw P, Colgan T, Murphy J, DePetrillo
D, Lickrish G, Laframboise S, Rosen B (2001) Does histology influence
prognosis in patients with early-stage cervical carcinoma? Cancer 92:
2999–3004
Gustafsson L, Ponten J, Zack M, Adami HO (1997) International incidence
rates of invasive cervical cancer after introduction of cytological
screening. Cancer Causes Control 8: 755–763
Hakulinen T, Abeywickrama KH (1985) A computer program package for
relative survival analysis. Comput Programs Biomed 19: 197–207
Hemminki K, Li X, Mutanen P (2001) Age-incidence relationships and time
trends in cervical cancer in Sweden. Eur J Epidemiol 17: 323–328
Hermanek P, Sobon LH (1987) TNM-Classification of Malignant Tumours.
4th revised edn. UICC International Union Against Cancer. Berlin:
Springer Verlag
Hildesheim A, Hadjimichael O, Schwartz PE, Wheeler CM, Barnes W,
Lowell DM, Willett J, Schiffman M (1999) Risk factors for rapid-onset
cervical cancer. Am J Obstet Gynecol 180: 571–577
Hopkins MP, Morley GW (1991) A comparison of adenocarcinoma and
squamous cell carcinoma of the cervix. Obstet Gynecol 77: 912–917
Lai CH, Hsueh S, Hong JH, Chang TC, Tseng CJ, Chou HH, Huang KG, Lin
JD (1999) Are adenocarcinomas and adenosquamous carcinomas
different from squamous carcinomas in stage IB and II cervical cancer
patients undergoing primary radical surgery? Int J Gynecol Cancer 9:
28–36
Levi F, Lucchini F, Negri E, Franceschi S, la Vecchia C (2000) Cervical
cancer mortality in young women in Europe: patterns and trends. Eur J
Cancer 36: 2266–2271
Liu S, Semenciw R, Probert A, Mao Y (2001) Cervical cancer in Canada:
changing patterns in incidence and mortality. Int J Gynecol Cancer 11:
24–31
Mitchell H, Medley G, Gordon I, Giles G (1995) Cervical cytology reported
as negative and risk of adenocarcinoma of the cervix: no strong evidence
of benefit. Br J Cancer 71: 894–897
Nakanishi T, Ishikawa H, Suzuki Y, Inoue T, Nakamura S, Kuzuya K (2000)
A comparison of prognoses of pathologic stage Ib adenocarcinoma
and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 79:
289–293
Nieminen P, Kallio M, Hakama M (1995) The effect of mass screening on
incidence and mortality of squamous and adenocarcinoma of cervix
uteri. Obstet Gynecol 85: 1017–1021
Parkin DM, Nguyen-Dinh X, Day NE (1985) The impact of screening on the
incidence of cervical cancer in England and Wales. Br J Obstet Gynaecol
92: 150–157
Pilch H, Gunzel S, Schaffer U, Tanner B, Brockerhoff P, Maeurer M, Hockel
M, Hommel G, Knapstein PG (2001) The presence of HPV DNA in
cervical cancer: correlation with clinico-pathologic parameters and
prognostic significance: 10 years experience at the Department of
Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer
11: 39–48
Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, Richart
RM, Isacson C (2000) Prevalence of human papillomavirus DNA in
different histological subtypes of cervical adenocarcinoma. Am J Pathol
157: 1055–1062
Quinn M, Babb P, Jones J, Allen E (1999) Effect of screening on incidence of
and mortality from cancer of cervix in England: evaluation based on
routinely collected statistics. BMJ 318: 904–908
Sasieni P, Adams J (1999) Effect of screening on cervical cancer mortality in
England and Wales: analysis of trends with an age period cohort model.
BMJ 318: 1244–1245
Sasieni P, Adams J (2001) Changing rates of adenocarcinoma and
adenosquamous carcinoma of the cervix in England. Lancet 357:
1490–1493
Schwartz SM, Daling JR, Shera KA, Madeleine MM, McKnight B, Galloway
DA, Porter PL, McDougall JK (2001) Human papillomavirus and
prognosis of invasive cervical cancer: a population-based study. J Clin
Oncol 19: 1906–1915
Sigurdsson K (1993) Effect of organized screening on the risk of cervical
cancer. Evaluation of screening activity in Iceland, 1964–1991. Int J
Cancer 54: 563–570
Stockton D, Cooper P, Lonsdale RN (1997) Changing incidence of invasive
adenocarcinoma of the uterine cervix in East Anglia. J Med Screen 4: 40–
43
van Ballegooijen M, Hermens R (2000) Cervical cancer screening in the
Netherlands. Eur J Cancer 36: 2244–2246
Visser O, Coebergh JW, Otter R (1997) Gynaecological Tumours in the
Netherlands 1989–1993. Utrecht: The Netherlands Cancer Registry
Visser O, Coebergh JW, Schouten LJ, van Dijck JAAM (2001) Incidence of
cancer in the Netherlands 1997. Utrecht: Vereniging van Integrale
Kankercentra
Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J,
Parkin DM (2000) International trends in incidence of cervical cancer: II.
Squamous-cell carcinoma. Int J Cancer 86: 429–435
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV,
Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is
a necessary cause of invasive cervical cancer worldwide. J Pathol 189:
12–19
Incidence and survival of cervical cancer
S Bulk et al
839
British Journal of Cancer (2003) 89(5), 834–839 & 2003 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y